Stock Research: Sanofi India

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Sanofi India

BSE:500674 INE058A01010
29
  • Value
    65
  • Growth
    5
  • Safety
    Safety
    45
  • Combined
    16
  • Sentiment
    56
  • 360° View
    360° View
    29
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sanofi India Limited manufactures and trades drugs and pharmaceuticals. The company focuses on therapeutic areas including diabetes (Lantus, Toustar), epilepsy (Frisium), cardiology (Cardace), allergy (Allegra, Avil), and pain care (Combiflam). It operates mainly in India, with a manufacturing facility in Goa and around 12 contract manufacturing organizations. In the last fiscal year, the company had a market cap of $1577 million, profits of $119 million, revenue of $235 million, and 991 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 29 (better than 29% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sanofi India are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Sanofi India. The consolidated Sentiment Rank has a good rank of 56, which means that professional investors are more optimistic about the stock than for 56% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 65 or better than 65% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 45, meaning that the share price of Sanofi India is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 5. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
45 35 43 55
Growth
5 11 31 7
Safety
Safety
65 83 75 97
Sentiment
56 83 45 94
360° View
360° View
29 59 43 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
100 97 87 97
Opinions Change
50 50 50 50
Pro Holdings
n/a 50 25 92
Market Pulse
9 84 29 27
Sentiment
56 83 45 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
45 35 43 55
Growth
5 11 31 7
Safety Safety
65 83 75 97
Combined
16 23 47 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
53 42 50 50
Price vs. Earnings (P/E)
39 36 29 39
Price vs. Book (P/B)
10 10 14 43
Dividend Yield
78 67 76 82
Value
45 35 43 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
23 23 32 8
Profit Growth
12 12 59 32
Capital Growth
1 19 17 9
Stock Returns
21 47 83 25
Growth
5 11 31 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
79 84 82 92
Refinancing
20 32 32 48
Liquidity
88 90 88 92
Safety Safety
65 83 75 97

Similar Stocks

Discover high‑ranked alternatives to Sanofi India and broaden your portfolio horizons.

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Rede D'Or São Luiz

BOVESPA:RDOR3
Country: Brazil
Industry: Health Care Facilities
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.